ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The history of CML has changed dramatically thanks to the introduction in the 1990’s of tyrosine kinase inhibitors, which are drugs capable of blocking the constitutive activation of BCR–ABL1.